Wednesday, March 20, 2013

Now accepting speaker submissions for Antibody Engineering & Therapeutics Conference

Announcing IBC’s 24th Annual International Conference
Annual Meeting of The Antibody Society
December 8-12, 2013
Hyatt Regency Huntington Beach Resort & Spa
Huntington Beach, CA

Now Accepting Speaking Proposals:

For 2013, IBC’s Antibody Engineering and Therapeutics is moving to a refreshing new beachfront location in Huntington Beach, CA, convenient to 3 airports – LAX, LGB and SNA.

Join us December 8-12, 2013 at the world’s leading forum for the exchange of cutting-edge protein engineering science and antibody therapeutics now in development.

Merging Science with Technology to Accelerate Antibodies to Market …

Now in its 24th year, Antibody Engineering has earned its reputation by consistently offering the most current academic research findings and most recent industry updates. Our attendees come back year after year for the information they need to stay abreast of the latest scientific trends in the antibody field. World-renowned scientists from across the globe convene at this event to share best practices and new approaches to exploit antibodies for developing novel medicines and vaccines. Learn about both the basic science of antibody engineering and the latest preclinical/clinical data, including safety and efficacy studies of the most cutting-edge antibody therapeutics now in development.

Are you interested in presenting?
We are looking for scientific presentations in the topic areas shown below. If you have a suggested presentation idea or a new topic, we want to hear from you - submit your abstract today (or no later than April 19):
  • - Systems biology/systems immunology of antibodies – how is everything connected?
  • - Alternative antibody formats: Mixtures, oligoclonals and polyclonals
  • - Anatomy/physiology of antibody distribution in different biological systems
  • - Intracellular antibodies
  • - Antibody library design and affinity maturation techniques
  • - Deep-sequencing of antibody responses
  • - Linkers and conjugation strategies for antibodies
  • - Immunomodulatory antibodies for cancer therapy and other diseases
  • - Non-cancer antibodies: infectious disease, non-malignant disease, autoimmune, CNS
  • - Clinical successes and failures – what have we learned?
  • - Antibody effector function
  • - Immunogenicity
  • - Antibodies as probes for intracellular post-translational modifications
  • - Cell biology of membranes, receptors and signaling leading to new targets for antibodies
  • - The Interface between humoral and cell-mediated immunity in cancer
  • - Non-antibody scaffolds
  • - Tumor targeting strategies: Why does so little antibody get into the tumor? How to improve?
  • - Physiology of tissue degradation
  • - Dealing with off target toxicity and PK/PD of proteins
  • - Clinical design strategies for antibody drugs, including phase 1 and phase 0 trial design
  • - Biomarkers, imaging and companion diagnostics for antibody drugs
  • - Building in manufacturability to your antibodies, optimization techniques for production
  • - Patient enrichment strategies for mAb therapies
  • - Antibodies by design: bioinformatics and modeling strategies to develop target-biased libraries
  • - Molecular engineering and design strategies
  • - Antibody administration: local and targeted delivery, alternative delivery approaches
  • - Gene-based Ab Expression - the intersection of Abs and gene therapy
  • - Antibodies in a complex environment
  • - From receptor biology to therapy
  • - Antibody-drug conjugates: preclinical and clinical updates
  • - Alternative antibody scaffolds, multifunctional antibodies , bispecifics, combinations
  • - Antibody activity and animal models
  • - Modulating half-life of antibody therapeutics
  • - Development status of early stage therapeutic antibodies
  • - Diagnostic applications of antibodies

If your talk is accepted, you will receive a formal invitation to speak at the conference. This invitation will reflect a deadline for you to send a final presentation title and 60-word abstract. Your abstract and presentation must describe scientific results and must not contain marketing or business development content.

Interested in Sponsoring or Exhibiting at this conference?
With over 800 attendees, this conference is a fantastic venue for promoting your antibody engineering and antibody drug development related technologies, products and services. For more information on sponsorship opportunities or to reserve your exhibit space, contact Sherry Johnson,

Share this article with your social network, just click below to share now!

No comments :

Post a Comment